Alnylam announces u.s. food and drug administration acceptance of supplemental new drug application for vutrisiran for the treatment of attr amyloidosis with cardiomyopathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the u.s. food and drug administration (fda) has accepted for review the company's supplemental new drug application (snda) for vutrisiran, an investigational rnai therapeutic in development for the treatment of attr amyloidosis with cardiomyopathy (attr-cm). based on the company's use of a priority review voucher, the fda has set an action date goal of mar.
ALNY Ratings Summary
ALNY Quant Ranking